For decades, statins have been the first-line therapy for lowering cholesterol and preventing heart disease. These medications, including atorvastatin, simvastatin, and rosuvastatin, are prescribed to millions worldwide.

While statins are highly effective at reducing LDL (“bad”) cholesterol levels, emerging research suggests that their use may come with unintended consequences — particularly related to muscle damage and increased cardiovascular risk.

Statins and Muscle Damage

Statins work by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol production. However, this pathway also plays a critical role in the production of coenzyme Q10 (CoQ10), a nutrient vital for mitochondrial energy production, especially in muscles.

Several studies show that statin therapy can cause:

• Muscle pain and weakness (myopathy)
• Muscle inflammation (myositis)
• Severe muscle breakdown (rhabdomyolysis) in rare cases [1]

Even in people who do not experience obvious symptoms, muscle cell damage may still occur at a microscopic level, affecting cardiac muscle as well as skeletal muscle [2].

Could Statins Increase Cardiovascular Risk?

Ironically, while statins reduce cholesterol, muscle damage — especially to the heart muscle — may actually increase cardiovascular risks over time. Mitochondrial dysfunction, triggered by CoQ10 depletion, has been linked to:

• Weakened heart function
• Heart failure development
• Arrhythmias (irregular heart rhythms) [3]

Additionally, some observational studies have raised concerns that lower cholesterol levels due to statins don’t always translate to improved outcomes in every population, especially among older adults [4].

While statins remain a valuable tool for certain high-risk individuals, it’s essential to recognize that lowering cholesterol is not the same as improving heart health.

Muscle damage, mitochondrial dysfunction, and nutrient depletion are real concerns that should be addressed, especially with long-term statin use.

Patients on statins should consider:

• Regular monitoring for muscle symptoms
• Discussing CoQ10 supplementation with their healthcare provider
• Exploring alternative or complementary strategies to manage cardiovascular risk holistically

 References

1. Thompson PD, Clarkson P, Karas RH. “Statin-associated myopathy.” JAMA. 2003;289(13):1681–1690. https://doi.org/10.1001/jama.289.13.1681 
2. Dirks AJ, Jones KM. “Statin-induced apoptosis and skeletal myopathy.” Am J Physiol Cell Physiol. 2006;291(6):C1208–C1212. 
3. Okita K, et al. “Statin therapy and mitochondrial function: evidence and possible mechanisms.” Curr Atheroscler Rep. 2017;19(11):44. 
4. Ravnskov U, Diamond DM, Hama R, et al. “LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature.” Expert Rev Clin Pharmacol. 2018;11(10):959–970.